Aduro Biotech, Inc. (NASDAQ:ADRO) received a $18.00 price objective from investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 88.48% from the company’s previous close.
ADRO has been the subject of a number of other research reports. BidaskClub cut Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Zacks Investment Research cut Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Canaccord Genuity set a $30.00 price target on Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. William Blair reissued an “outperform” rating on shares of Aduro Biotech in a research note on Monday, October 2nd. Finally, Cowen and Company started coverage on Aduro Biotech in a research note on Tuesday, July 18th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $19.00.
Shares of Aduro Biotech (NASDAQ ADRO) opened at 9.55 on Tuesday. The company has a 50-day moving average price of $10.84 and a 200-day moving average price of $10.89. The stock’s market capitalization is $712.54 million. Aduro Biotech has a 52-week low of $8.75 and a 52-week high of $15.52.
Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The business had revenue of $5.90 million for the quarter, compared to the consensus estimate of $3.98 million. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The company’s revenue for the quarter was down 84.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.03 earnings per share. On average, equities analysts anticipate that Aduro Biotech will post ($1.35) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Aduro Biotech, Inc. (ADRO) PT Set at $18.00 by HC Wainwright” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/10/19/aduro-biotech-inc-adro-pt-set-at-18-00-by-hc-wainwright.html.
In related news, CEO Stephen T. Isaacs sold 40,000 shares of Aduro Biotech stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $12.19, for a total value of $487,600.00. Following the completion of the transaction, the chief executive officer now owns 144,025 shares in the company, valued at approximately $1,755,664.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Blaine Templeman sold 3,557 shares of Aduro Biotech stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $10.99, for a total value of $39,091.43. Following the completion of the transaction, the vice president now owns 65,275 shares of the company’s stock, valued at approximately $717,372.25. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 342,745 shares of company stock valued at $3,956,397. 6.60% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the business. Legal & General Group Plc increased its stake in Aduro Biotech by 11.2% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after buying an additional 1,043 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in shares of Aduro Biotech by 15.9% during the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 2,119 shares during the last quarter. Tudor Investment Corp ET AL boosted its holdings in shares of Aduro Biotech by 34.8% during the 1st quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 3,984 shares during the last quarter. Voya Investment Management LLC boosted its holdings in shares of Aduro Biotech by 15.3% during the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 2,515 shares during the last quarter. Finally, American International Group Inc. boosted its holdings in shares of Aduro Biotech by 7.1% during the 1st quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 1,447 shares during the last quarter. Institutional investors own 35.05% of the company’s stock.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.